Cbdmd Inc Stock Price, News & Analysis

cbdMD (NYSE: YCBD) reported Q2 fiscal 2025 results showing continued growth and improved financial performance. Net sales increased 8.6% to $4.7 million compared to $4.4 million in the prior year period. The company significantly narrowed its operating loss to $485,000 from $1.5 million year-over-year, while gross margin improved from 59% to 62%. Key developments include the completion of Series A Preferred Stock conversion, adding nearly $7 million to equity base and eliminating $6.7 million in dividend liability. The company executed an 8:1 reverse stock split, resulting in approximately 8.9 million common shares outstanding. cbdMD's Herbal Oasis brand expanded distribution into Alabama, Florida, and North Carolina, with all four flavors receiving medals at the 2025 High Spirits Awards. Direct-to-consumer sales represented 77% of total revenue at $3.6 million, while wholesale revenue grew to $1.1 million. The company ended the quarter with $1.8 million in cash and achieved compliance with NYSE American listing standards following the capital restructuring.

cbdMD, Inc. (NYSE American: YCBD), a leading CBD company, has announced it will host a conference call to discuss its second quarter fiscal year 2025 financial results for the period ending March 31, 2025. The conference call is scheduled for Thursday, May 15, 2025, at 4:20 p.m. Eastern Time. Participants can join via USA/Canada (833-821-3524) or International (647-846-2919) dial-in numbers. A replay will be available through dedicated phone lines and a webcast replay link will remain accessible until May 15, 2026.

Herbal Oasis, a hemp-derived THC-infused social seltzer brand owned by cbdMD (YCBD), has announced a new distribution agreement with Carolina Premium Beverage to serve Charlotte, NC and surrounding counties starting May 2025. This expansion marks the brand's entry into its third state in two months, following successful launches in Alabama and Florida.

The beverage brand, targeting sober-curious and health-conscious consumers, combines hemp-derived THC, CBG, and functional mushrooms to create an alcohol alternative. The partnership with Carolina Premium Beverage aims to accelerate market penetration in Charlotte, the company's home territory, while supporting its broader Southeast expansion strategy.

Herbal Oasis has achieved significant recognition at the 2025 High Spirits Awards, securing multiple medals for their hemp-infused beverages. Their products earned a Gold Medal for Mango Bliss, Silver Medals for Lemon Lift and Tropical Twist, and a Bronze Medal for Berry Fusion.

Launched in late 2024, the brand competes in the 'Other Infused Beverage Products' category, offering non-alcoholic alternatives combining hemp-derived THC, CBG, and functional mushrooms. The recognition comes just four months after their national launch.

The market outlook appears promising, with Euromonitor International projecting hemp-derived THC beverage sales to reach $4.1 billion by 2028. The company has begun distribution in Alabama, Florida, and North Carolina, with plans for expansion throughout spring and summer, while also offering nationwide delivery through their website.

cbdMD (YCBD) has announced two significant corporate actions effective May 6, 2025: the automatic conversion of its 8% Series A Cumulative Convertible Preferred Stock into Common Stock, and a one-for-eight reverse stock split.

The preferred stock conversion will convert each preferred share into thirteen common shares, eliminating approximately $6.7 million in accrued dividend liabilities and $4.0 million in perpetual annual obligations. The last trading day for preferred stock will be May 5, 2025.

Following both corporate actions, YCBD's outstanding common shares will consolidate from approximately 71.26 million to 8.91 million shares. The reverse split will be effective after market close on May 6, 2025, with post-split trading beginning May 7, 2025. The company will maintain its NYSE American listing under the YCBD symbol with a new CUSIP number.

cbdMD (NYSE: YCBD) announced shareholder approval for the automatic conversion of its Series A Preferred Stock into Common Stock at its April 10, 2025 annual meeting. The conversion will transform each preferred share into thirteen common shares, eliminating approximately $6.7 million in accrued dividend payments and $4 million in annual dividend obligations.

The company also secured shareholder approval for:

• Election of seven directors for the 2026 term
• Appointment of Cherry Bekaert LLP as independent auditor
• Authorization for a potential reverse stock split ranging from 1:3 to 1:10 within one year

CEO Ronan Kennedy stated this conversion will enhance their capital structure, enable reinvestment in growth initiatives, and support continued NYSE American listing requirements while removing barriers to strategic M&A activities.

Herbal Oasis, a hemp-derived THC-infused social seltzer brand, has announced its distribution expansion into Alabama and select Florida Panhandle markets starting late March 2025. The alcohol-free beverage, owned by cbdMD, combines hemp-derived THC, CBG, and functional mushrooms.

Each 12-ounce can features:

• Hemp-Derived Delta-9 THC + CBG
• 2,500mg of functional mushrooms (Lion's Mane, Reishi, Cordyceps)
• Nano-liposomal technology for 10-15 minute onset

The product will be available across major Alabama cities and Florida Panhandle locations through grocery chains, convenience stores, wellness shops, and hospitality venues. According to Euromonitor International, hemp-derived THC beverage sales doubled in 2024 and are projected to reach $4.1 billion by 2028, representing a 1,600% increase from $239 million in 2023.

cbdMD (NYSE: YCBD) has reached a significant milestone in its UK regulatory journey as its Novel Food dossier (RP793) advances to the final phase of assessment with the UK Food Standards Agency (FSA). The company's proprietary CBD isolate, with over 97% purity, received a positive safety assessment on February 28, 2025.

The FSA's evaluation confirms that cbdMD's ingredient meets UK food safety standards, is free from contaminants and controlled cannabinoids like THC, and supports safe consumption levels for adults. The company initiated this process in March 2021 and became the first U.S. brand to receive dossier validation in February 2022.

This development positions cbdMD among the few companies approaching full Novel Food authorization in the UK's £800 million CBD market. The achievement is expected to enhance consumer confidence and expand market share in the regulated CBD industry.

cbdMD (NYSE: YCBD) reported financial results for Q1 FY2025 ended December 31, 2024. The company achieved $5.1 million in revenue, marking a 12% sequential increase from Q4 FY2024, though representing a 19.1% year-over-year decrease. Notable achievements include the company's first-ever positive non-GAAP Adjusted EBITDA of $214,000 and a net income of $15,000, improving by approximately $1 million from the prior year.

The company maintained a 66% gross profit margin and reduced its operating loss to $80,000 from $1.1 million in the previous year. Direct-to-consumer sales accounted for 77% of total revenue at $4.0 million, while wholesale revenue increased by 22% to $1.1 million. The company ended the quarter with $2.0 million in cash and became debt-free following the conversion of remaining convertible notes in January 2025.

cbdMD also launched Herbal Oasis, a new ready-to-drink hemp-derived beverage brand, and announced plans for its 2025 annual meeting, including a proposal to convert Series A Preferred stock and accrued dividends into common stock.